Theravance Biopharma, Inc. (TBPH) Earnings History
Annual and quarterly earnings data from 2011 to 2024
Loading earnings history...
TBPH EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
TBPH Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -72.9% | -87.6% |
| 2023 | 29.3% | -97.6% | -96.1% |
| 2022 | -23.5% | -179.1% | 1698.5% |
| 2021 | -250.1% | -466.1% | -360.6% |
| 2020 | 100.0% | -414.2% | -386.9% |
Download Data
Export TBPH earnings history in CSV or JSON format
Free sign-in required to download data
Theravance Biopharma, Inc. (TBPH) Earnings Overview
As of May 8, 2026, Theravance Biopharma, Inc. (TBPH) reported trailing twelve-month net income of $29M, reflecting -15.0% year-over-year growth. The company earned $0.57 per diluted share over the past four quarters, with a net profit margin of -87.6%.
Looking at the long-term picture, TBPH's historical earnings data spans multiple years. The company achieved its highest annual net income of $872M in fiscal 2022.
Theravance Biopharma, Inc. maintains positive profitability with a gross margin of 100.0%, operating margin of -72.9%, and net margin of -87.6%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including INVA ($504M net income, 63.8% margin), PRGO (-$1.82B net income, -33.5% margin), SUPN (-$29M net income, -5.4% margin), TBPH has room to improve margins relative to the peer group. Compare TBPH vs INVA →
TBPH Earnings vs Peers
Earnings metrics vs comparable public companies
TBPH Historical Earnings Data (2011–2024)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$56M | -2.2% | -$47M | $-1.15 | -87.6% | -72.9% |
| 2023 | -$55M | -106.3% | -$56M | $-1.00 | -96.1% | -97.6% |
| 2022 | $872M | +537.3% | -$92M | $-1.26 | 1698.5% | -179.1% |
| 2021 | -$199M | +28.3% | -$258M | $-2.87 | -360.6% | -466.1% |
| 2020 | -$278M | -17.6% | -$298M | $-4.46 | -386.9% | -414.2% |
| 2019 | -$236M | -9.7% | -$252M | $-4.25 | -322.1% | -343.1% |
| 2018 | -$216M | +24.5% | -$239M | $-3.99 | -357.0% | -395.5% |
| 2017 | -$285M | -49.7% | -$260M | $-5.45 | -1855.0% | -1690.6% |
| 2016 | -$191M | -4.6% | -$180M | $-4.26 | -391.9% | -371.0% |
| 2015 | -$182M | +23.1% | -$182M | $-5.34 | -432.6% | -431.8% |
See TBPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TBPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TBPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTBPH — Frequently Asked Questions
Quick answers to the most common questions about buying TBPH stock.
Is TBPH growing earnings?
TBPH EPS fell to $0.57, with earnings declining -15.0%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $29M.
What are TBPH's profit margins?
Theravance Biopharma, Inc. net margin is -87.6%, with operating margin at -72.9%. Below-average margins reflect competitive or cost pressures.
How consistent are TBPH's earnings?
TBPH earnings data spans 2011-2024. The declining earnings trend is -15.0% YoY. Historical data enables comparison across business cycles.